Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Chavez

Showing results (231-240 of 285) with videos related to

Pageof 29
Sort By:
Blood Advances|July 28, 2025
Targeting S100A9-mediated inflammation: A novel therapeutic approach for CLLAngimar Uriepero-Palma, Maria Elena Marquez, Eugenia Payque, et al.
Ejhaem|July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphomaVincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Ejhaem|July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomaLoretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Transplantation and Cellular Therapy|May 17, 2022
Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for LymphomaAnna Barata, Aasha I Hoogland, Anuhya Kommalapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Transplantation and Cellular Therapy|April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell TherapyAasha I Hoogland, Anna Barata, Jennifer Logue, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Pageof 29

Showing results (231-240 of 285) with videos related to

Sort By:
Pageof 29
Blood Advances|July 28, 2025
Targeting S100A9-mediated inflammation: A novel therapeutic approach for CLLAngimar Uriepero-Palma, Maria Elena Marquez, Eugenia Payque, et al.
Ejhaem|July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphomaVincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Ejhaem|July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomaLoretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Transplantation and Cellular Therapy|May 17, 2022
Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for LymphomaAnna Barata, Aasha I Hoogland, Anuhya Kommalapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Transplantation and Cellular Therapy|April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell TherapyAasha I Hoogland, Anna Barata, Jennifer Logue, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Pageof 29